Study Background

This pilot clinical trial evaluates the efficacy of adding Blinatumomab (bispecific antibody) and either Dasatinib or Imatinib to standard chemotherapy in patients with Philadelphia chromosome–positive (Ph+) or ABL‑class Ph‑like B‑cell acute lymphoblastic leukemia (B‑ALL). Current therapy relies solely on tyrosine kinase inhibitors and chemotherapy, which are associated with high rates of resistance and relapse, underscoring the need for novel combinations.

Population and Design

This is a Phase 2 study, currently RECRUITING, with a start date of 2025‑05‑30. It enrolls pediatric, adolescent, and young adult patients diagnosed with Ph+ or ABL‑class Ph‑like B‑ALL. The primary objectives are safety and early efficacy, with the primary endpoint being overall response rate and incidence of adverse events.

Current Treatment Landscape and Differentiation

Current standard of care for Ph+ B‑ALL consists of tyrosine kinase inhibitors combined with chemotherapy, while Blinatumomab is used only in relapsed or refractory settings. This study investigates the simultaneous application of a tyrosine kinase inhibitor, immune activation via Blinatumomab, and chemotherapy to potentially increase complete remission rates and reduce relapse risk.

Expected Benefits and Impact

If successful, a Blinatumomab‑based combination regimen could become a new standard treatment option for early‑phase Ph+ and Ph‑like B‑ALL. Demonstrating synergy between immunotherapy and targeted therapy would also provide a rationale for extending similar combination strategies to other hematologic malignancies.